EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy

Sergej Kudruk iD, Connor M Forsyth iD, Michelle Z Dion iD, Jenny K Hedlund Orbeck iD, Jingqin Luo, Robyn S Klein iD, Albert H Kim iD, Amy B Heimberger, Chad A Mirkin iD, Alexander H Stegh, Natalie Artzi

Proceedings of the National Academy of Sciences · 20.02.2024 · 121 (8)

DOI: 10.1073/pnas.2306973121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 12.02.2024. Verfasst von Sergej Kudruk und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Northwestern University, Evanston, IL 60208. Hauptthemen laut MEDLINE: Glioblastoma, Nanoparticles, Nanostructures, Brain Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, HHS | NIH | National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Integrating multimodal neuro- and nanotechnology-enabled precision immunotherapies with extant systemic immunotherapies may finally provide a significant breakthrough for combatting glioblastoma (GBM). The potency of this approach lies in its ability to train the immune system to efficiently identify and eradicate cancer cells, thereby creating anti-tumor immune memory while minimizing multi-mechanistic immune suppression. A critical aspect of these therapies is the controlled, spatiotemporal delivery of structurally defined nanotherapeutics into the GBM tumor microenvironment (TME). Architectures such as spherical nucleic acids or poly(beta-amino ester)/dendrimer-based nanoparticles have shown promising results in preclinical models due to their multivalency and abilities to activate antigen-presenting cells and prime antigen-specific T cells. These nanostructures also permit systematic variation to optimize their distribution, TME accumulation, cellular uptake, and overall immunostimulatory effects. Delving deeper into the relationships between nanotherapeutic structures and their performance will accelerate nano-drug development and pave the way for the rapid clinical translation of advanced nanomedicines. In addition, the efficacy of nanotechnology-based immunotherapies may be enhanced when integrated with emerging precision surgical techniques, such as laser interstitial thermal therapy, and when combined with systemic immunotherapies, particularly inhibitors of immune-mediated checkpoints and immunosuppressive adenosine signaling. In this perspective, we highlight the potential of emerging treatment modalities, combining advances in biomedical engineering and neurotechnology development with existing immunotherapies to overcome treatment resistance and transform the management of GBM. We conclude with a call to action for researchers to leverage these technologies and accelerate their translation into the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaNanoparticlesNanostructuresBrain NeoplasmsHumansImmunotherapyNanotechnologyTumor Microenvironment

Stichwörter der Autor:innen

glioblastomaimmunotherapyneuro-nanotechnology

Autor:innen und Institutionen

  • Department of Chemistry, Northwestern University, Evanston, IL 60208.
  • International Institute for Nanotechnology, Northwestern University, Evanston, IL 60208.
  • Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115.
  • Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • The Brain Tumor Center, Alvin J. Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, MO 63110.
  • Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110.

ORCID-Profile: Sergej Kudruk, Connor M Forsyth, Michelle Z Dion, Jenny K Hedlund Orbeck, Robyn S Klein, Albert H Kim, Chad A Mirkin

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • HHS | NIH | National Cancer Institute
  • HHS | National Institutes of Health
  • MIT | Deshpande Center for Technological Innovation, Massachusetts Institute of Technology
  • BWH | Brigham Research Institute
  • National Science Foundation

Zitieren

APA

Kudruk, S., Forsyth, C. M., Dion, M. Z., Hedlund Orbeck, J. K., Luo, J., Klein, R. S., Kim, A. H., Heimberger, A. B., Mirkin, C. A., Stegh, A. H., & Artzi, N. (2024). Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy. Proceedings of the National Academy of Sciences, 121(8). https://doi.org/10.1073/pnas.2306973121

Vancouver

Kudruk S, Forsyth CM, Dion MZ, Hedlund Orbeck JK, Luo J, Klein RS, et al. Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy. Proceedings of the National Academy of Sciences. 2024;121(8). doi:10.1073/pnas.2306973121

BibTeX
@article{Kudruk2024,
  author = {Kudruk, Sergej and Forsyth, Connor M and Dion, Michelle Z and Hedlund Orbeck, Jenny K and Luo, Jingqin and Klein, Robyn S and Kim, Albert H and Heimberger, Amy B and Mirkin, Chad A and Stegh, Alexander H and Artzi, Natalie},
  title = {Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {8},
  doi = {10.1073/pnas.2306973121}
}
Kostenlos starten →